Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Hanmi Pharmaceutical
Company facts
- Status
- KOSPI 128940 · ISIN KR7128940004
- Founded
- 2010-07-05
- CEO
- 황상연
- Headquarters
- 경기도 화성시 팔탄면 무하로 214
- Industry
- KSIC 21212
- Fiscal year end
- 12
- Links
- Filings · DART · Quote · finance.naver.com · Website
- Source
- DART
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | 1,490,887 | 1,495,502 | 1,547,531 |
| Operating income | 220,691 | 216,186 | 257,799 |
| Net income | 165,366 | 140,431 | 187,136 |
| Total assets | 1,898,668 | 2,020,840 | 2,137,598 |
| Total liabilities | 798,458 | 780,089 | 714,744 |
| Total equity | 1,100,211 | 1,240,752 | 1,422,853 |
Unit: KRW million · Consolidated statements · Source DART 사업보고서
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
National R&D projects (NTIS)
59
item
32,352,384,000
Cumulative government R&D funding (KRW)
Largest projects
- 차세대 당뇨병 치료제 HM11260C 글로벌 임상 및 제품화 연구 2013 · 다부처
- 차세대 지속형 글루카곤 HM15136 선천성 고인슐린증 치료제 개발 위한 글로벌 임상 및 제품화 연구 2022 · 다부처
- 경구용 항암제 오라테칸의 개발 2008 · 보건복지가족부
Korean patent filings (KIPRIS)
802
item
Recently published patents
- 복약편의성이 개선된 두타스테리드 및 탐스로신을 포함하는 경구용 복합제제 20260911
- 수불용성 중합체를 이용해 복용 편의성을 개선한 위식도 역류질환 치료제 20260630
- EP300 단백질 분해제 및 이의 용도 20260629
- GLP-1 유사체를 포함하는 경구투여용 리포솜 조성물 및 이의 제조방법 20260629
- 리나글립틴, 엠파글리플로진 및 메트포르민을 포함하는 약제학적 복합제제 20260624
Papers with affiliated authors (OpenAlex)
113
item
Papers by year
| 2025 |
|---|
| 113 |
Companies in the same readouts
- Dong-A ST
- Chugai Pharmaceutical
- Eli Lilly
- Hangzhou Zhongmei Huadong
- Jiangsu Hengrui
- Eccogene
- Novo Nordisk
- LG H&H
Last updated 2026-09-21